Vktx presentation to shareholders

Vktx presentation to shareholders

@financepresentations

5 Followers

6 days ago 63

Business #InvestmentHighlights #CorporatePresentation #MetabolicDiseases #Therapeutics #ClinicalTrials

Vktx presentation to shareholders

@financepresentations6 days ago

Corporate Presentation
October 2024

1/61

Forward-Looking Statements
This presentation contains statements about our future expectations, pl…

2/61

Investment Highlights
● Developing novel therapeutics for metabolic and endocrine diseases
ဝ Mult…

3/61

Pipeline Overview
Potential data events expected over next 3-6 months
ဝ VK2735 Oral: Additional P…

4/61

VK2735: Dual GLP-1/GIP Receptor Agonist
Metabolic Disorders

5/61

GLP-1/GIP Dual Agonists for Metabolic Disorders
6
GLP-1/GIP Receptor Co-Activation and Downstream…

6/61

Novel Peptide-Based Dual Agonists
7
● Potent binding (<500nM) to human
GLP-1 and GIP receptors
…

7/61

VK2735 Metabolic Effects Exceed GLP-1 Mono-Agonist Effects
● GLP-1 receptor activity similar to
…

8/61

VK2735 Phase 1 Clinical Study Design
9
● Randomized, placebo-controlled, stacked SAD/MAD study de…

9/61

VK2735 Phase 1 SAD Results
10
● All planned SAD cohorts were completed
ဝ 0.25 mg, 0.5 mg. 1.0 mg…

10/61

% Change in BW: -1.8% -2.5% -3.7% -4.1% -7.4% -7.8%
Placebo-adjusted: - -0.7% -1.9% -2.3% -5.6% -6…

11/61

VK2735 Phase 1 Results: Rapid, Progressive Weight Loss Observed
Change From Baseline Body Weight O…

12/61

-7
-6
-5
-4
-3
-2
-1
0
0.5 mg
(n=6)
1.5 mg
(n=6)
1.5/3/5/5 mg
(n=7)
3/5/5/7.5 mg
(n=…

13/61

VK2735 Phase 1 MAD Study: GI Tolerability Summary
14
● Majority of all reported AEs (98%) mild or…

14/61

15/61

VK2735 VENTURE Phase 2 Obesity Study Design
16
D1 W4 W19
Randomize
Placebo (n=35)
Follow-up
2…

16/61

17
● Well-balanced demographics among cohorts
● Gender breakout generally 2:1 to 3:1 women to men…

17/61

-15
-12
-9
-6
-3
0
Placebo
(n=34)
VK2735
2.5 mg
(n=35)
VK2735
5.0 mg
(n=35)
VK2735
1…

18/61

VENTURE Phase 2 Results: Rapid, Progressive Weight Loss Observed
Change From Baseline Body Weight …

19/61

0
15
30
45
60
75
90
Placebo
(n=34)
VK2735
2.5 mg
(n=35)
VK2735
5.0 mg
(n=35)
VK2735
…

20/61

% Change in BW: -14.7% -17.1% -8.0% -10.8% -15.6% -26.5% -22.5%
Duration in Weeks 13 16 20 26 48 4…

21/61

Number of subjects reporting (%) Placebo
(n=35)
VK2735
2.5 mg
(n=35)
VK2735
5 mg
(n=35)
VK2…

22/61

VENTURE Phase 2 Study: GI Tolerability Summary
23
● Majority (95%) GI specific TEAEs among VK2735…

23/61

Time Course of GI AEs Through 13 Weeks; Combined Cohorts
24
● GI AEs most common, expected per GL…

24/61

VENTURE Phase 2 Study Takeaways and Next Steps
25
● Up to 14.7% weight loss from baseline observe…

25/61

VK2735: Oral Formulation
Metabolic Disorders

26/61

Oral Formulation Overview
27
● Exploratory work pursued to develop oral formulation of VK2735
● …

27/61

Oral VK2735: Early PoC Signal in Animals
28
● Efficacy signals from DIO rodent model and primate …

28/61

VK2735-101 Oral Study
29
● Phase 1 MAD study design
● Single-site, placebo-controlled extension …

29/61

% Change in BW: -2.1% -0.3% -0.9% -1.1% -3.2% -5.3%
Placebo-adjusted: - 1.8% 1.2% 1.0% -1.1% -3.3%…

30/61

Oral VK2735 Phase 1 Results: Weight Change After 34 Days
31
-6
-5
-4
-3
-2
-1
0
Placebo
(…

31/61

20
0 0
33
63
86
0 0 0 0
25
57
0
20
40
60
80
100
Placebo
(n=10)
2.5 mg
(n=8)
2.5/5…

32/61

% of subjects reporting
“early satiety” 10% 0% 17% 33% 38% 57%
% change in BW -2.1% -0.3% -0.9% …

33/61

VK2735 Oral Phase 1 Results: Progressive Weight Loss Observed
Change From Baseline Body Weight Ove…

34/61

% Change in BW: -2.1% -0.3% -0.9% -1.1% -3.2% -5.3%
Placebo-adjusted: - 1.8% 1.2% 1.0% -1.1% -3.3%…

35/61

VK2735 Oral Phase 1 Study: GI Tolerability Summary
36
● All GI-specific TEAEs among VK2735 subjec…

36/61

37/61

VK2735 Oral Phase 1 Study Takeaways and Next Steps
38
● Up to 5.3% mean weight loss observed afte…

38/61

VK2809: Selective Thyroid Receptor-β Agonist
NASH/MASH

39/61

Thyroid Hormone Receptor Overview
40
Nuclear hormone receptors: 2 main types
Positive effects
…

40/61

VK2809: Unique Liver-Targeted Characteristics
VK2809, Novel Prodrug
VK2809A, Potent TRβ Agonist,…

41/61

VK2809: Phase 2b VOYAGE Study

42/61

VOYAGE Study: 12-Month Phase 2b Study of VK2809
43
D1 M3
MRI-PDFF
M13
Safety
Randomize
Place…

43/61

-60
-50
-40
-30
-20
-10
0
Placebo
(n=62)
VK2809
1 mg QD
(n=17)
VK2809
2.5 mg QD
(n=59…

44/61

VK2809 Demonstrates Consistent Liver Fat Reduction in T2D
● 44% of VOYAGE patients had
type 2 di…

45/61

VK2809 Demonstrates Consistent Liver Fat Reduction Across F2, F3
● VOYAGE enrolled approximately
…

46/61

0
15
30
45
60
75
90
Placebo
(n=48)
VK2809
1 mg QD
(n=14)
VK2809
2.5 mg QD
(n=55)
VK2…

47/61

0
15
30
45
60
75
Placebo
(n=41)
VK2809
1 mg QD
(n=14)
VK2809
2.5 mg QD
(n=52)
VK2809
…

48/61

0
15
30
45
60
Placebo
(n=41)
VK2809
1 mg QD
(n=14)
VK2809
2.5 mg QD
(n=52)
VK2809
5 m…

49/61

0
10
20
30
40
50
Placebo
(n=41)
VK2809
1 mg QD
(n=14)
VK2809
2.5 mg QD
(n=52)
VK2809
…

50/61

-25
-20
-15
-10
-5
0
5
Placebo
(n=46)
VK2809
1 mg QD
(n=14)
VK2809
2.5 mg QD
(n=50)
…

51/61

52/61

VK2809 VOYAGE Takeaways and Next Steps
53
● Achieves primary endpoint demonstrating robust reduct…

53/61

X-Linked Adrenoleukodystrophy
VK0214: Selective Thyroid Receptor-β Agonist

54/61

% Difference: -42.0% -79.7% -76.6% -54.3%
p-value: <0.0001 <0.0001 <0.0001 <0.0001
VK0214: Summar…

55/61

TRβ and X-Linked Adrenoleukodystrophy
Caused by mutation in gene for the ATP-Binding Cassette tran…

56/61

% Change: 3.8% -0.7% -12.5% -21.4% -19.5% -19.1% -18.9%
p-value: - 0.2827 0.0230 0.0040 0.0060 0.0…

57/61

VK0214 Phase 1b Study in Adrenomyeloneuropathy
58
Screening
21 days
D1 D7 D14 D21 D28 D35
Ran…

58/61

Financial Summary
59
● Capital structure and summary financials
Capital Structure1In ‘000s Finan…

59/61

Investment Highlights
● Developing novel therapeutics for metabolic and endocrine diseases
ဝ Mult…

60/61

Corporate Presentation
October 2024

61/61

@financepresentations

Drag Me

Comments 0 Info

Vktx presentation to shareholders

@financepresentations

This presentation discusses forward-looking statements regarding our pipeline of novel therapeutics for metabolic and endocrine diseases, including VK2735 for obesity, VK2809 for NASH, and VK0214 for X-ALD. Key findings from recent clinical studies, including promising efficacy and safety data, are presented to highlight our strategic initiatives and future directions.

Business

#InvestmentHighlights #CorporatePresentation #MetabolicDiseases #Therapeutics #ClinicalTrials

This website uses cookies to improve your experience. By using this site, you consent to the use of cookies.